. Author manuscript; available in PMC: 2015 Jan 9.

Published in final edited form as: Am J Cancer Ther Pharmacol. 2014 Sep 7;2(1):21–32.

Table 1.

Patient characteristics at study entry (n = 16)

Age (yr)	Average	66.5
Age (yr)	Range	48–83
Race (%)	White (14/16)	87.5%
Race (%)	Non-white (2/16)	12.5%
Gleason score sum (%)	≥ 7(13/16)[GS 8 4 pts]	81.3%
Gleason score sum (%)	< 7 (3/16)	18.7%
Baseline PSA (ng/mL)	Mean+/−SD	3.9 +/− 2.1
	Median	3.5
	Range	1.5–8.2
PSA doubling time Prior to treatment	Average	8.3 Months
PSA doubling time Prior to treatment	Range	2.7 – 20.4 Months
Prior treatment	Prostatectomy only (1/16)	6.25%
	Radiotherapy only (3/16)	18.75%
	Prostatectomy and salvage radiotherapy (9/16)	56.25%
	Radiotherapy and hormonal therapy (1/16)	6.25%
	Prostatectomy and salvage radiotherapy and hormonal therapy (2/16)	12.5%
	Intermittent hormonal therapy (4/16)	25%